君实生物上半年营收增近五成但仍未扭亏,研发投入发力增三成,港股刚募资10亿港元

读创客户端
Aug 27, 2025

8月26日晚间,君实生物发布2025年半年报,上半年实现营业收入11.68亿元,同比增长49%;归母净亏损收窄36%至4.13亿元,归母扣非净亏损减少至4.78亿元。君实生物称,营业收入的增长主要得益于商业化药品的销售收入与上年同期相比增长,上半年实现药品销售收入10.59亿元,同比增长49%,其中拓益于国内市场实现销售收入9.54亿元,同比增长约42%。归属于上市公司股东的净利润、基本每股收益、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10